Stockscreener 앱 받기
0.8733
42.23%
0.2593
시간 외 거래:
.84
-0.0333
-3.81%
전일 마감가:
$0.614
열려 있는:
$0.9235
하루 거래량:
120.64M
Relative Volume:
58.49
시가총액:
$732.51K
수익:
$104.00K
순이익/손실:
$-8.39M
주가수익비율:
-0.042
EPS:
-20.7895
순현금흐름:
$-8.31M
1주 성능:
+32.26%
1개월 성능:
-13.53%
6개월 성능:
-86.91%
1년 성능:
-94.33%
1일 변동 폭
$0.8008
$1.35
1주일 범위
$0.6005
$1.35
52주 변동 폭
$0.6005
$19.30
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Compare BDRX vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
0.8733 | 515.02K | 104.00K | -8.39M | -8.31M | -20.79 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-08 | 개시 | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr 주식(BDRX)의 최신 뉴스
Biodexa partners with Syngene for MTX240 manufacturing By Investing.com - Investing.com Australia
171.7M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADS for resale via equity line - Stock Titan
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today? - Benzinga
Weeks after Otsuka license, Biodexa secures MTX240 trial manufacturing - Stock Titan
Biodexa’s eRapa Program: Global Expansion and European Gains - StocksToTrade
BDRX SEC FilingsBiodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan
No approved FAP drug: Biodexa opens global eRapa access - Stock Titan
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADSs for resale under equity line - Stock Titan
943.4M Ordinary Shares resale by selling holders (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (BDRX) flags going-concern doubts amid ongoing losses - Stock Titan
Biodexa (NASDAQ: BDRX) grows pipeline but warns on 2026 funding needs - Stock Titan
Preliminary Results for the Year Ended 31 December 2025 - GlobeNewswire
Biodexa partners with Tanner Pharma for FAP drug early access By Investing.com - Investing.com Australia
Biodexa Launches Global Early Access Program for eRapa for - GlobeNewswire
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group - markets.businessinsider.com
Biodexa partners with Tanner Pharma for FAP drug early access - Investing.com
Biodexa opens first non-trial access to eRapa for FAP patients - Stock Titan
Biodexa (NASDAQ: BDRX) director reports detailed stock option holdings - stocktitan.net
Biodexa Pharmaceuticals changes ADR ratio to meet Nasdaq rules By Investing.com - Investing.com Australia
Biodexa Pharmaceuticals announces ADR ratio change - MSN
Biodexa Pharmaceuticals Announces Reverse ADR Split to Support Nasdaq Compliance - tipranks.com
Biodexa Pharmaceuticals (BDRX) Announces ADR Ratio Change - GuruFocus
Biodexa Pharmaceuticals changes ADR ratio to meet Nasdaq rules - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change to Comply with Nasdaq Minimum Bid Price Requirement - quiverquant.com
Reverse ADR split at Biodexa (Nasdaq: BDRX) targets Nasdaq $1 bid rule - Stock Titan
ADR Ratio Change - Bitget
Biodexa Pharmaceuticals (NASDAQ: BDRX) director lists stock option position - Stock Titan
Biodexa (NASDAQ: BDRX) CEO lists detailed stock option holdings - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) director details ADS option stake - Stock Titan
Biodexa (BDRX) CFO details multi-year stock option grants - Stock Titan
Biodexa Pharmaceuticals (BDRX) director Simon Turton reports initial equity holdings - Stock Titan
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients - ChartMill
New U.S. group for those facing near-100% colon cancer risk, backed by Biodexa - Stock Titan
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Upgraded at Wall Street Zen - Defense World
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer - Finviz
New molecular glue drug aims to tackle deadly stomach tumors - Stock Titan
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST - markets.businessinsider.com
Biodexa licenses Otsuka’s molecular glue compound for GIST treatment By Investing.com - Investing.com India
Biodexa licenses Otsuka’s molecular glue compound for GIST treatment - Investing.com
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary - Yahoo Finance
Biodexa pharmaceuticals appoints Fiona Sharp as CFO and board member By Investing.com - Investing.com India
Biodexa pharmaceuticals appoints Fiona Sharp as CFO and board member - Investing.com
Biodexa Pharmaceuticals Faces Market Challenges as Stocks Decline - StocksToTrade
Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Expands By 298.4% - Defense World
Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering - TipRanks
Biodexa Pharmaceuticals stock falls after $10 million public offering By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals stock falls after $10 million public offering - Investing.com
Biodexa Pharmaceuticals Plc Adr (BDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
1.47%
자본화:
|
볼륨(24시간):